Table 1 Summary of treatment response, overall survival and risk factors in newly-diagnosed unfit patients with acute myeloid leukemia treated with Venetoclax and hypomethylating agent therapy.
From: Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms
VIALE- A study Venetoclax + Azacitidine | Mayo Clinic study Venetoclax + Azacitidine or Decitabine | |
|---|---|---|
N | 286 | 400 |
CR/CRi rate | 67% | 62% |
Genetic predictors of superior response | Presence of IDH1/IDH2MUT Presence of NPM1MUT | Presence of IDH2MUT Presence of NPM1MUT Presence of DDX41MUT Absence of FLT3-ITDMUT Absence of RUNX1MUT Absence TP53MUT |
Relapse rate | 52% | 40% |
Median Overall survival | 14.7 months | 13.2 months |
Risk factors for survival | Absence of MRD-negative CR/CRi Presence of Adverse cytogenetics | Absence of CR/CRi Presence of Adverse cytogenetics Absence of IDH2MUT Presence of TP53MUT Presence of KRASMUT Presence of KMT2Ar |
Reference | DiNardo et al., NEJM 2020 | Gangat et al., AJH 2025 |
